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Anticancer Drugs
Abstract
Plant‐derived anticancer drugs play a large role in anticancer pharmaceuticals. Through reviewing the four
major types of plant anticancer drugs, namely vinca alkaloids, taxane diterpenoids, podophyllotoxin lignans,
and camptothecin quinoline alkaloids, this article illustrates the development process, current status, existing
challenges, and future perspective of the plant anticancer drug production. Moreover, this review explains
how various biotechnologies, from the mature elicitation strategy to the “omics” techniques that are still
undergoing development, can be applied to address the challenges in improving the production of the
plant‐sourced anticancer drugs.
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Le Zhao, Zengyi Shao, and Jacqueline V Shanks
8.1
Natural Products as Anticancer Drugs
Natural products (secondarymetabolites) have been a rich repertoire for isolating
medical compounds for several millennia. Over 50% of the currently available
drugs are natural compounds or their synthetic derivatives with similar chemical
structures. Plants, because of their necessity to defend against pathogens and
predators, are a rich source of medicinal compounds, especially anticancer com-
pounds. Plant-derived anticancer natural products can be divided into several
classes: vinca alkaloids, taxane diterpenoids, podophyllotoxin (PTOX) lignans,
camptothecin (CPT) quinoline alkaloids, and others. This review focuses on the
recent progress on improving the production of the aforementioned four types
of anticancer drugs in various homologous and heterologous culture systems and
the biotechnology advancements in in vitro culture, metabolic engineering, and
pathway elucidation.
8.2
Anticancer Drug Production
8.2.1
Production Systems
There are ﬁve potential directions to obtain valuable natural products originating
from plants: direct extraction, chemical synthesis, plant cell and tissue culture,
endophytic fungi culture, and heterologous synthesis.
As secondary metabolites, natural products usually exist at very low concen-
trations in native plants, making direct extraction from plants laborious and
costly [1]. Some parameters, such as plant growth rate, individual abundance,
and seasonal availability, could further weaken the robustness of an extraction
process [2]. Even so, current commercial production of most plant-derived
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anticancer natural products is still based on plant extraction because of the lack
of other mature approaches. Among the four categories of anticancer drugs,
only taxane diterpenoids are produced through plant cell culture, and the other
three are all puriﬁed from plants in the corresponding commercial production
processes.
One possible alternative production method is through chemical synthesis.
Examples of the total chemical synthesis of many natural, plant-derived anti-
cancer drugs have been reported in the literature [3–6]. However, in terms
of commercial production, the total chemical synthesis is still not economical
and sustainable, mainly because it involves many reaction steps, uses harsh
solvents, and usually ends up with a low yield of the target product that is often
mixed with various structurally similar byproducts. Instead, semi-chemical
synthesis procedures are favored for generating derivatives that present better
pharmaceutical properties from either extracted natural products or metabolic
intermediates [7].
Biotechnology progress in plant in vitro cell and tissue culture provides alter-
natives to produce valuable secondary metabolites [8]. Suspension cells and hairy
roots, being amenable to large-scale industrial application, are the two most in-
depth studied cultures [9]. Plant suspension cells are biosynthetically totipotent
with the potential to produce all the compounds in parent plants. Rao et al. have
listed the plant species whose cell cultures produce more secondary metabolites
than the intact plants [10]. Paclitaxel is themost typical representative of the com-
mercialized anticancer drugs produced in plant cell cultures [11].The bottlenecks
of cell culture development are low product yields, genetic instability, andmetabo-
lite variability [12]. Hairy roots in most cases grow with the similar rates as cell
culture but with higher biochemical and genetic stability. In addition, since hairy
roots are diﬀerentiated, compartmentalization of portions of cellular pathways
may assist in the production of toxic intermediates and metabolites. They keep
most of the properties of the natural roots and contain metabolites synthesized in
the roots.This distinction is important since transport of metabolites to and from
other plant tissues is not present in a root culture [13].
Plant endophytic fungi play important roles in plant secondary metabolite
biosynthesis. Some endophytic fungi produce the samemetabolites as their hosts.
Corresponding to the four categories of anticancer drugs, a great number of
endophytic fungi have been isolated and characterized with the ability to produce
these anticancer compounds [14]. Although no fermentation based on plant
endophytic fungi has been commercialized because of the low and sometimes
unstable yields, fungal fermentation holds a great potential considering fungi
have been widely applied in food, pharmaceutical, and agriculture industries for
a long time. In order to make fungi-produced anticancer drugs commercially
viable, secondary metabolic pathways in endophytic fungi and their dynamic
interactions with plant hosts need to be studied well.
Finally, heterologous production in microbes has been of interest for decades.
Synthetic biology tools and expanding biochemical and genetic knowledge of
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plant medicinal pathways bring a new promise to this option. Some micro-
bial hosts, especially Escherichia coli (E. coli) and Saccharomyces cerevisiae
(S. cerevisiae), have been widely used in the industry because of their fast
doubling times, ease of genetic manipulation, and mature large-scale cul-
ture technologies. Existing bottlenecks are that some reactions involved in
the entire biosynthesis have not been fully identiﬁed and sometimes plant-
sourced proteins cannot fold and function properly in microbial expression
systems. So far, the highest titer of producing a precursor of an anticancer
drug in microbes has been demonstrated by the synthesis of taxadiene [15],
the precursor of paclitaxel, in E. coli, which will be discussed in detail in
Section 8.3.2.
8.2.2
Approaches for Improving Production
Elicitation is a common strategy to increase secondary metabolite levels in intact
plants, plant tissues, and cell cultures. Among the various elicitors, jasmonic acid,
its conjugates, and precursors, collectively known as jasmonates (JAs), are eﬀec-
tive in activating the biosynthesis of many plant secondary metabolites through
initiating plant defense mechanisms against pathogens and herbivores [16]. In
Taxus cell suspension cultures, the amounts of paclitaxel and baccatin III (one of
the intermediates in the paclitaxel biosynthetic pathway) increased signiﬁcantly
after treatment with methyl jasmonate (MeJA) [17]. Jasmonic acid was found
to be the most eﬀective elicitor to increase CPT production in Camptotheca
acuminate cell suspension cultures in comparison with other biotic and abiotic
elicitors [18].
In principle, precursor feeding is another approach to increase the titer of ﬁnal
products; however, since the expression of the involved genes is subjected to
strict regulation, increasing precursor concentration does not usually increase
the metabolic ﬂuxes proportionally. In a ﬁnal approach, immobilization of plant
cells is a method that enhances cell-to-cell contact. The associated changes in
cellular physiology can bring up the levels of certain secondary metabolites [19].
In microbial production systems, various metabolic engineering strategies are
often applied to improve production. In contrast, plant metabolic engineering
is still in its infancy and many toolkits are needed. Particle bombardment and
Agrobacterium-mediated transformation are the two frequently used methods
to introduce foreign DNA molecules, and protocols have been established for
transforming Catharanthus roseus (vinca alkaloids producer) [20, 21] and Taxus
species (taxane diterpenoids producer) [22, 23]. Most recently, Agrobacterium-
mediated transformation has been applied to Podophyllum hexandrum (PTOX
lignans producer) successfully, making a further step toward expressing the
desired genes in P. hexandrum to improve the titer of podophyllotoxin and
optimize other traits [24].
Besides the production of anticancer compounds in native organisms, heterol-
ogous synthesis, mainly in microbes, brings new opportunities and technical
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challenges. The advantages of heterologous synthesis include the following: (i)
ease of genetic manipulation and culture processing in heterologous hosts, (ii)
lack of complicated regulation belonging to the native organisms, and (iii) a
simpliﬁed puriﬁcation process without contamination by structurally similar
metabolites that exist in the native organisms. Meanwhile, the challenges are also
apparent. First of all, enabling a heterologous host for producing anticancer drugs
usually requires the expression of multiple genes, and expressing plant-sourced
proteins in microbial systems is sometimes challenging. Second, the accumu-
lation of some intermediates caused by unbalanced gene expression may result
in toxicity issues. Furthermore, some metabolites require plant organelles for
their synthesis, so that an alternative scaﬀold in the microbial host will have to
be created. Regardless of these challenges, many eﬀorts have been attempted to
produce anticancer drugs in heterologous hosts, such as E. coli and S. cerevisiae.
Recently, the rapid development in synthetic biology points out additional
directions to tackle the challenges in this area; for example, Martin et al. [25]
developed E. coli strains as platform hosts for the production of terpenoid
compounds.
8.2.3
Gene Discovery
One of the prerequisites for applying metabolic engineering strategies is the
comprehensive knowledge of a biosynthetic pathway. However, none of the anti-
cancer drug biosynthetic pathways has been fully elucidated. To characterize a
pathway, metabolites and the genes involved in the pathway need to be identiﬁed.
In the post-genomic era, even though the genome sequences of many non-model
plants (including the medicinal plants discussed in this review) are still unknown,
a large number of expressed sequence tags (ESTs) or cDNA sequences are
available in databases, based on which the functions of some plant genes have
been predicted through homology search and subsequently been conﬁrmed
by experiments. Enzymes belonging to plant cytochrome P450-dependent
monooxygenases are the examples that have been identiﬁed by this means.
They share high sequence similarities and have a well-established subfamily
classiﬁcation [26].
Although none of the genomes of the plant species that produce anticancer
drugs has been sequenced and many genes are still not annotated, a great amount
of “omics” data including transcriptomics, proteomics, and metabolomics have
been generated. Comparative analysis of the “omics” data either individually or in
combination from diﬀerent plant tissues or from diﬀerent elicitation conditions
provides a strategy to narrow down the search scope of the uncharacterized
genes. The examples of using “omics” data in gene discovery can be represented
by the characterization of ﬁve genes in podophyllotoxin biosynthetic pathway,
which will be discussed in detail in Section 8.3.3. Similar “omics” eﬀorts for
all the plant-derived anticancer drugs will also be introduced in the ensuing
sections.
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8.3
Important Anticancer Natural Products
8.3.1
Vinca Alkaloids
Vinblastine and vincristine are terpenoid indole alkaloids (TIAs) isolated from
the pantropical plant C. roseus (Madagascar periwinkle). They have been used for
centuries throughout the world as a traditional medicine to treat diseases such as
diabetes and eye infections. When researchers began to analyze C. roseus in the
late 1950s, vincristine and vinblastine were found to be able to lower the number
of white cells in blood. Through decades of research, the medicinal mechanism
of vinblastine and vincristine has been well studied, and these two compounds
are currently widely applied in chemotherapies for many types of cancers [27]. To
decrease their toxicity and explore broader pharmacological applications, several
semisynthetic derivatives were synthesized, among which vindesine and vinorel-
bine have been marketed. Together with vinblastine and vincristine, these four
compounds have diﬀerent pharmaceutical proﬁles and are used to treat diﬀerent
types of cancers [28]. Figure 8.1 shows the structures of these four vinca alkaloids.
Semisynthesis of C. roseus vinca alkaloid derivatives was summarized by van der
Heijden et al. [29].
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Figure 8.1 Chemical structures of vinblastine, vincristine, vindesine, and vinorelbine.
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C. roseus produces more than 130 diﬀerent TIAs and is the only source for
obtaining vinblastine and vincristine.Thebiosynthetic pathway ofTIA inC. roseus
is complex and highly branched (Figure 8.2). The isolation of vinblastine and vin-
cristine from C. roseus is laborious and costly due to their relatively low levels in
the plant. Approximately 500 kg of dried leaves are needed in order to isolate 1 g
of vinblastine [30]. The low production of vinblastine and vincristine stimulated
a great number of research projects aiming at improving productivity. Research
has been focusing on production of vinca alkaloids either by fermentation of endo-
phytic fungi inC. roseus or by large-scale culturing of plant suspension cells, hairy
roots, and other tissues. More than 183 endophytic fungi have been isolated from
diﬀerent tissues ofC. roseus, and some of themwere reported to possess the ability
to produce either vinblastine or vincristine. Among the fungi isolated from Chi-
nese C. roseus, it was reported that one endophytic fungus, Fusarium oxysporum,
produced vincristine, and another endophytic fungi species, Alternaria sp., pro-
duced vinblastine. F. oxysporum isolated from the Indian species produced 76 μg
vinblastine and 67 μg vincristine in 1 l of fermentation broth, and the dimers were
characterized by HPLC (high-performance liquid chromatography), MS (mass
spectrometry), and 1H NMR (nuclear magnetic resonance) [31]. For Fusarium,
the biosynthetic pathways for the production of vinblastine and vincristine from
tryptophan and geraniol have not been elucidated.
C. roseus cell suspension and hairy root cultures do not produce the two bisin-
dole alkaloids vinblastine and vincristine, because of the inability to synthesize
one of the monoterpene indole alkaloids (MIAs), vindoline (Figure 8.2). Vindoline
condenses with another MIA, catharanthine, forming the bisindole alkaloids.
In suspension cell cultures, transcripts of N-methyltransferase (NMT), desace-
toxyvindoline 4-hydroxylase (D4H), and deacetylvindoline acetyltransferase
(DAT) are absent, and consequently the biosynthesis of vindoline is blocked
[32–34]. Root cultures lack the idioblast and laticifer, which are specialized cell
types for the late steps of vindoline synthesis, so vindoline cannot be produced
in hairy root cultures as well. A comprehensive RNA-seq data from diﬀerent
tissues of C. roseus, including leaf, ﬂower, and root, also indicated that enzymes
involved in the vindoline and vinblastine pathways are restricted to aerial tissues
[35]. The intermediate metabolite tabersonine in hairy root culture accumulates,
and is converted via the lochnericine and hörhammericine branch, instead of the
vindoline branch [36]. The high ﬂux through tabersonine in hairy roots indicates
the potential of this culture type for the production of vindoline if an active
tabersonine to vindoline pathway could be engineered into the roots. In multiple
shoot cultures, vindoline and catharanthine levels are comparable to those in
intact plants, and vinblastine level is greater than that in callus culture but less
than that in the parent plant [37].
Various strategies to increase alkaloids levels, including adjusting the medium,
temperature, light, and aeration, have been reviewed [38, 39]. Many plant phy-
tohormones and elicitors, both biotic and abiotic, have been applied to increase
alkaloids accumulation [29, 39]. Several studies showed that MeJA, ethylene, and
fungal elicitors individually or conjointly promoted vindoline accumulation in
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either callus culture or shoot culture [32, 40], and transcript analysis further indi-
cated that several genes in the vindoline biosynthetic pathway were upregulated
by these elicitors.
As mentioned earlier, C. roseus suspension cells and hairy roots do not pro-
duce anticancer drugs mainly because the vindoline pathway is blocked in those
two systems. Through intricate manipulation of several elicitors of the vindoline
pathway and inhibitors of the bypass, vindoline and vinblastine were produced
in suspension cells as determined by HPLC [41]. The highest vinblastine yield of
810 μg g−1 DW was reported, which was much higher than that in the mature
plant (12 μg g−1 DW). However, this report would be strengthened if additional
evidence could be provided to support that the vindoline biosynthetic pathway is
active in suspension cell cultures, such as the NMR andMS/MS data of vindoline
and transcription levels of all the enzymes in the vindoline pathway.
In general, suspension cell cultures are derived from dediﬀerentiation-derived
calluses (DDCs). However, recent studies suggest that the DDC cells are not
real totipotent stem cells because the callus formation might not entail a sim-
ple backward reprogramming of the dediﬀerentiation process [42] and some
deleterious genetic or epigenetic changes could occur [43, 44]. In 2015, an
undiﬀerentiated cambial meristematic cell (CMC) of C. roseus was isolated and
a comparison between CMCs and DDCs was made [45]. One of the conclusions
of that study was that CMCs are more stable than DDCs. CMCs remained white
and transparent after 8–10 rounds of subculturing, while DDCs showed yellow
or brown color after two rounds. Interestingly, the transcriptome proﬁle of the
genes and metabolites involved in the TIA pathway are also diﬀerent between
CMCs and DDCs. Vindoline was detected in CMCs with several types of culture
media but not in any of the DDC media. Zhou et al. reported the transcriptome
and metabolite proﬁles of a 2-year-old CMC line from C. roseus [46]. The CMCs
grew very stable and could accumulate vindoline and several other MIAs. The
highest titer of vindoline (7.45mg l−1) was achieved in a 5-l stirred hybrid
airlift bioreactor fermentation treated with 10mM 𝛽-cyclodextrin and 150𝜇M
MeJA. Nonetheless, vindoline was measured via HPLC analysis only, and the
transcription analysis for the key enzyme, NMT, was not performed; therefore,
their (promising) results should be interpreted with caution.
Metabolic engineering of C. roseus cell suspensions, hairy root cultures, and
even intact plants has been studied with the aim of increasing TIA accumulation.
Overexpression of transcription factors or overexpression of a TIA enzyme or a
combination of enzymes has been the main strategy to date. Precursor feeding
strategies are often combined with these experiments in order to determine rate-
limiting steps.These eﬀorts often only result inmodest improvement of TIA accu-
mulation (Table 8.1) since transcriptional regulation is hierarchical and a large
portion of the regulatory network is still unclear.
Heterologous expression of the TIA synthetic pathway in non-native plant
hosts and microbial hosts is under development and will potentially pave the
way for producing interesting TIA from hosts that grow faster and are easier
to be cultured. Most of the heterologous expression eﬀorts are focused on
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tryptophan decarboxylase (TDC), strictosidine synthase (STR), and strictosidine
𝛽-D-glucosidase (SGD), the three enzymes in the upstream of the TIA pathway
(Figure 8.2). These three genes, individually or in combination, were expressed in
tobacco suspension cells, tobacco plants, Cinchona oﬃcinalis hairy root culture,
other plant species tissue cultures, yeast, and E. coli, with the precursor fed to the
culture [29]. Table 8.1 lists some examples of genetic engineering in non-native
hosts. In 2015, as the last two unknown genes in vindoline biosynthetic pathway
branch, tabersonine 3-oxygenase (T3O) and tabersonine 3-reductase (T3R),
catalyzing the “hydration” reaction from 16-methoxytabersonine to 16-methoxy-
2,3-dihydro-3-hydroxytabersonine were isolated, De Luca et al. assembled the
seven-step pathway from tabersonine to vindoline in yeast [58]. By feeding with
tabersonine or one of the intermediates, namely 16-methoxytabersonine, the
engineered yeast strains were able to accumulate vindoline and other inter-
mediates and secreted 95% of the MIAs to the medium. In another example,
as the genes involved in the upstream secologanin synthetic pathway were all
characterized in succession, O’Connor’s group introduced the whole pathways
in S. cerevisiae together with other genetic manipulations to produce the central
intermediate strictosidine, without any precursor feeding [57].
Great eﬀorts have been made in the metabolic engineering of the upstream
pathways in vinblastine and vincristine biosynthesis, especially in the past
2 years. However, the pathway from the central intermediate strictosidine to
tabersonine is still unclear. In addition, it would bemore challenging and complex
to produce bisindole alkaloids than MIAs in heterologous systems. To further
explore the unknown genes, pathways, and regulators using methods other than
the classical biochemical approaches that heavily rely on protein puriﬁcation
and enzyme assay, information provided by EST, transcriptome, proteome, and
metabolome could be very insightful for predicting and characterizing unknown
genes in the TIA pathway.
Very recently, in-depth proteome mining of C. roseus suspension cell was
conducted. Among the total 1663 identiﬁed proteins, 63 enzymes were identiﬁed
to be potentially involved in secondary metabolism, of which 22 were involved
in the TIA biosynthetic pathway and 16 were predicted as putative transporters
[59]. In this study, four known enzymes in TIA pathway were conﬁrmed, and gene
candidates in other seven reaction steps, mainly in the secologanin (precursor
of TIA) biosynthetic pathway, were proposed based on the proteomics data in
combination with analogy with other species.
Bioinformatic techniques to discover new genes have relied more heavily on
RNA-Seq data in recent years. One example is the discovery of the last four
missing enzymes in the secologanin biosynthetic pathway, also named the iridoid
pathway [60]. With a huge RNA-Seq dataset including diﬀerent tissues and
induction conditions, the complete linkage hierarchical clustering maps were
constructed and genes that had the predicted enzyme activities and carried the
same expression patterns with the known genes in the pathway were screened
as the candidate genes. CathaCyc, a speciﬁc pathway database (PDB) derived
from C. roseus RNA-Seq datasets, is accessible online (http://www.cathacyc.org).
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CathaCyc presents a variety of tools for the visualization and analysis of metabolic
networks and “omics” data [61] and will certainly help in discovering missing
enzymes, studying metabolic pathway evolution, and, ultimately, improving
metabolic pathways originating from C. roseus.
Two common strategies to understand gene function in the TIA pathway are
“forward genetics” and “reverse genetics”. Forward genetics seeks the genetic basis
triggering a certain phenotype or trait, while reverse genetics studies which phe-
notypes arise from particular genetic sequences. Leslie van der Fits et al. success-
fully applied forward genetics to identify theORCA3gene, one of the transcription
factors in the TIA pathway, using C. roseus suspension cells by transferred DNA
(T-DNA) activation tagging [50]. With increasing knowledge of gene sequences,
reverse genetic techniques are in high demand. For example, RNA interference
(RNAi)-based gene silencing is one of the powerful tools in reverse genetics. RNAi
has been applied eﬀectively in C. roseus hairy root culture and cell suspension
culture [62–64] to decipher gene function. The success in introducing the virus-
induced gene silencing (VIGS) technique into the C. roseus plant [65] facilitated
the discovery of the last two enzymes in the vindoline biosynthetic pathway [58].
8.3.2
Taxane Diterpenoids
Paclitaxel (also named taxol), (Figure 8.3) is a diterpenoid discovered in 1967
from the bark of the Paciﬁc yew tree, Taxus brevifolia, working as a mitotic
inhibitor used in cancer chemotherapy. One of paclitaxel analogs, docetaxel
(Figure 8.3), is a semisynthetic compound produced from 10-deacetylbaccatine-
III. 10-deacetylbaccatine-III is an intermediate in the paclitaxel synthetic
pathway (Figure 8.4), which was found in relatively large amounts in the needles
of Taxus baccata (European yew tree). Various Taxus species produce taxol
and over 300 related compounds in total. Paclitaxel and docetaxel have been
approved by the Food and Drug Administration (FDA) for the treatment of
breast, lung, ovarian, and prostate cancers. In the past, paclitaxel was com-
mercially extracted from the barks of yew trees. This production method was
labor-intensive and unsustainable because the paclitaxel level in the natural
yew tree is quite low. Three or four 150–200-year-old trees were sacriﬁced in
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order to obtain the amount of paclitaxel needed for one cancer treatment [66].
Later, both paclitaxel and docetaxel could be chemically synthesized from
10-deacetylbaccatine-III, which was isolated from the twigs and needles of the
European yew. An even more sustainable approach is to produce paclitaxel via
large-scale plant cell suspension culture. Compared to the semisynthesis, the
advantage of large-scale plant cell suspension culture is that it eliminates the need
for numerous hazardous chemicals and consequently saves on waste disposal.
Hundreds of kilograms of paclitaxel can be produced in a 75 000-l bioreactor in a
single batch [67].
Although cell suspension cultures (DDC cells) have been used in the industry
to produce paclitaxel, the variability in product accumulation is still a key chal-
lenge to the regular commercial use [2]. In parallel to the examples shown in
Section 8.3.1, CMCs were isolated from Taxus cuspidate to produce paclitaxel
[68]. The CMCs demonstrated great advantages over the DDCs and overcame
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the obstacles associated with the commercial culture of DDCs. First, CMCs grew
much faster thanDDCs in bioreactors since theyweremore tolerant of shear stress
owing to some molecular properties, such as small and abundant vacuoles, thin
cell walls, and less aggregation. Second, CMCs were stable and could keep grow-
ing rapidly during 22months of culture.The biomass of CMCswas fourfold higher
than that from DDCs in the same culture condition, and the paclitaxel yield was
increased to 7.5-fold compared with the common DDC culture. In all, the devel-
opment of CMCs has a great potential for paclitaxel’s commercial production in
the future.
To decrease the cost of paclitaxel production, alternative production
approaches have been intensively explored. In 1993, the ﬁrst endophytic
fungus Taxomyces andreanae, which is able to produce paclitaxel, was isolated
[69]. From then on, over 50 paclitaxel-producing fungi have been isolated and
studied worldwide [70]. The reported highest titer of paclitaxel from fungi
fermentation is 478 μg l−1 [71], which is much lower than that obtained through
large-scale plant suspension culture (900mg l−1). Two important issues need
to be solved in the fungal system: the biosynthetic mechanism of paclitaxel is
unknown, and most fungi lose the capability of paclitaxel synthesis after being
cultured for several generations [72].
In addition, hairy root culture was attempted by two groups for paclitaxel pro-
duction. One of the hairy root lines, established using seedlings of T. cuspidate
(Korean yew), accumulated 52.5mg l−1 paclitaxel after 2weeks in a 20-l bioreac-
tor operating under MeJA induction [73]. The other hairy root culture generated
from the plantlets of Taxus×media (a hybrid species between T. cuspidate and T.
baccata) accumulated 210 μg g−1 DW paclitaxel following MeJA induction [74].
Applying metabolic engineering strategies in Taxus species is diﬃcult because
of the extremely low gene transformation eﬃciency. The total amount of taxanes,
especially the level of paclitaxel, has not increased signiﬁcantly via overexpressing
the pathway-related enzymes, knocking out the side-route enzymes, or overex-
pressing the enzymes in the elicitor pathway (Table 8.2). Clearly, more knowledge
of the genetic and biochemical regulation of the pathway is needed.
Much eﬀort has been made to express the paclitaxel synthesis genes in
non-native hosts, particularly in two microbial production hosts, S. cerevisiae
and E. coli (Table 8.2). In 2001, Huang et al. [87] expressed three genes in E.
coli and produced taxadiene, which is the ﬁrst terpenoid intermediate in the
paclitaxel synthetic pathway, at a titer of 1.3mg l−1. In 2006, DeJong et al. [85]
expressed eight genes in S. cerevisiae with the goal to produce one of the inter-
mediates, taxadien-5𝛼-acetate-10𝛽-ol (Figure 8.4). Analysis of the metabolites
showed 1mg l−1 taxadiene, a trace amount of taxadine-5𝛼-ol (∼25 μg l−1), and no
taxadien-5𝛼-acetate-10𝛽-ol, indicating that the ﬁrst cytochrome P450 hydrox-
ylation reaction had become a limitation in this expression system. In 2008,
Engels et al. [86] improved the taxadiene titer in S. cerevisiae to 9mg l−1. In 2010,
Gregory Stephanopoulos’ group [15] optimized an engineered E. coli strain
via sophisticated metabolic engineering approaches, improving the taxadiene
titer to 1 g l−1, which is the highest taxadiene level reported in non-native
8.3 Important Anticancer Natural Products 253
Ta
b
le
8.
2
Re
ce
nt
ex
am
p
le
s
of
us
in
g
m
et
ab
ol
ic
en
gi
ne
er
in
g
st
ra
te
gi
es
to
im
p
ro
ve
th
e
p
ro
du
ct
io
n
of
p
ac
lit
ax
el
.
H
os
ts
En
g
in
ee
ri
n
g
st
ra
te
g
ie
s
Ro
le
in
th
e
p
ac
lit
ax
el
p
at
hw
ay
Ex
p
re
ss
io
n
sy
st
em
M
ai
n
ob
se
rv
at
io
n
s
Na
tiv
eh
os
ts
O
ve
re
xp
re
ss
io
n
of
DB
AT
wi
th
M
eJ
A
eli
cit
at
io
n
[7
5]
Pa
th
wa
ye
nz
ym
e
T.
m
ai
re
ic
ell
su
sp
en
sio
n
In
cr
ea
se
in
ba
cc
at
in
III
an
d
pa
cli
ta
xe
l
O
ve
re
xp
re
ss
io
n
of
DB
AT
[7
6]
Pa
th
wa
ye
nz
ym
e
T.
ch
in
en
sis
ce
ll
su
sp
en
sio
n
1.7
-fo
ld
in
cr
ea
se
in
pa
cli
ta
xe
l
O
ve
re
xp
re
ss
io
n
of
TX
Sw
ith
M
eJ
A
eli
cit
at
io
n
[7
7]
Pa
th
wa
ye
nz
ym
e
T.
m
ed
ia
ce
ll
su
sp
en
sio
n
2.6
5-
fo
ld
in
cr
ea
se
in
to
ta
lt
ax
an
es
Kn
oc
ko
ut
of
ta
xo
id
14
𝛽
-h
yd
ro
xy
las
e(
T1
4O
H)
[7
8]
Si
de
-r
ou
te
pa
th
wa
ye
nz
ym
e
T.
m
ed
ia
ce
ll
su
sp
en
sio
n
De
cr
ea
se
in
th
et
hr
ee
by
pr
od
uc
ts
of
ta
xa
ne
s;
no
re
po
rt
ab
ou
t
pa
cli
ta
xe
ll
ev
el
O
ve
re
xp
re
ss
io
n
of
9-
cis
-e
po
xy
ca
ro
te
no
id
di
ox
yg
en
as
e[
79
]
En
zy
m
ei
n
th
ea
bs
cis
ic
ac
id
(A
BC
)b
io
sy
nt
he
tic
pa
th
wa
y
T.
ch
in
en
sis
ce
ll
su
sp
en
sio
n
1.2
-fo
ld
in
cr
ea
se
in
ab
sc
isi
ca
cid
2.8
-fo
ld
in
cr
ea
se
in
pa
cli
ta
xe
l
No
n-
na
tiv
e
ho
sts
Ex
pr
es
sio
n
of
TX
S[
80
]
Pa
th
wa
ye
nz
ym
e
Ar
ab
id
op
sis
th
al
ia
na
pl
an
t
60
μg
ta
xa
di
en
ep
er
ki
lo
gr
am
of
dr
yw
eig
ht
;a
let
ha
lp
he
no
ty
pe
Ex
pr
es
sio
n
of
TX
S[
81
]
Pa
th
wa
ye
nz
ym
e
To
m
at
o
pl
an
t
16
0m
gt
ax
ad
ien
ep
er
ki
lo
gr
am
fru
it;
as
lo
w
gr
ow
th
ph
en
ot
yp
e
Ex
pr
es
sio
n
of
TX
S[
82
]
Pa
th
wa
ye
nz
ym
e
M
os
sP
hy
sc
om
itr
ell
a
pa
ten
s
0.0
5%
fre
sh
we
igh
to
ft
iss
ue
Ex
pr
es
sio
n
of
TX
Sw
ith
M
eJ
A
eli
cit
at
io
n
[8
3]
Pa
th
wa
ye
nz
ym
e
Gi
ns
en
gr
oo
t
15
.9
μg
ta
xa
di
en
ep
er
gr
am
of
dr
y
we
igh
t
Ex
pr
es
sio
n
of
TX
Sw
ith
M
eJ
A
eli
cit
at
io
n
[8
4]
Pa
th
wa
ye
nz
ym
e
Ni
co
tia
na
be
nt
ha
m
ia
na
pl
an
t
∼
40
μg
ta
xa
di
en
ep
er
gr
am
of
dr
y
we
igh
t
Ex
pr
es
sio
n
of
eig
ht
ge
ne
si
n
th
e
ea
rly
pa
rt
of
pa
cli
ta
xe
l
bi
os
yn
th
et
ic
pa
th
wa
y[
85
]
Pa
th
wa
ye
nz
ym
e
Sa
cc
ha
ro
m
yc
es
ce
re
vi
sia
e
1m
gl
−
1
of
ta
xa
di
en
e∼
25
μg
l−
1
of
ta
xa
di
ne
-5
𝛼
-o
l (c
on
tin
ue
d
ov
er
lea
f)
254 8 Anticancer Drugs
Ta
b
le
8.
2
(C
on
tin
ue
d)
H
os
ts
En
g
in
ee
ri
n
g
st
ra
te
g
ie
s
Ro
le
in
th
e
p
ac
lit
ax
el
p
at
hw
ay
Ex
p
re
ss
io
n
sy
st
em
M
ai
n
ob
se
rv
at
io
n
s
Ex
pr
es
sio
n
of
TX
S,
an
in
cr
ea
se
in
pr
ec
ur
so
rp
oo
lb
yg
en
e
ov
er
ex
pr
es
sio
n
an
d
m
an
ip
ul
at
io
n
in
fe
ed
ba
ck
in
hi
bi
tio
n
an
d
re
gu
lat
or
s[
86
]
Pa
th
wa
ye
nz
ym
ea
nd
re
gu
lat
or
Sa
cc
ha
ro
m
yc
es
ce
re
vi
sia
e
9m
gl
−
1
of
ta
xa
di
en
e
Ex
pr
es
sio
n
of
TX
Sa
nd
tw
o
ge
ne
s
in
th
eg
er
an
ylg
er
an
yl
di
sp
ho
sp
ha
te
bi
os
yn
th
et
ic
pa
th
wa
y[
87
]
Pa
th
wa
ye
nz
ym
e
Es
ch
er
ich
ia
co
li
1.3
m
gl
−
1
of
ta
xa
di
en
e
Ex
pr
es
sio
n
of
TX
Sa
nd
ot
he
rg
en
es
in
up
str
ea
m
pa
th
wa
ys
wi
th
a
“m
ul
tiv
ar
iat
e-
m
od
ul
ar
”a
pp
ro
ac
h
[1
5]
Pa
th
wa
ye
nz
ym
e
Es
ch
er
ich
ia
co
li
1g
l−
1
of
ta
xa
di
en
e
Ex
pr
es
sio
n
of
TY
H5
𝛼
,T
AT
,
TY
H1
0𝛽
,a
nd
ot
he
rg
en
es
in
S.
ce
re
vi
sia
ew
ith
as
ta
bl
em
ut
ua
lis
tic
E.
co
li
an
d
S.
ce
re
vi
sia
e
co
ns
or
tiu
m
be
in
gc
on
str
uc
te
d
[8
8]
Pa
th
wa
ye
nz
ym
e
Es
ch
er
ich
ia
co
li
an
d
Sa
cc
ha
ro
m
yc
es
ce
re
vi
sia
e
co
ns
or
tiu
m
33
m
gl
−
1
of
ta
xa
di
ne
-5
𝛼
-o
l
1m
gl
−
1
of
ta
xa
di
en
-5
𝛼
-a
ce
ta
te
-1
0𝛽
-o
l
8.3 Important Anticancer Natural Products 255
hosts. Later, the same group expressed several genes catalyzing taxadiene into
subsequent intermediates in the paclitaxel pathway in S. cerevisiae and built a
stable mutualistic E. coli and S. cerevisiae consortium that produced 33mg l−1 of
taxadine-5𝛼-ol and 1mg l−1 of taxadien-5𝛼-acetate-10𝛽-ol [88].
To further increase the taxadiene level in E. coli, “omics” techniques were
used to elucidate the potential enzymes needed to be modiﬁed. Results from a
transcriptomics study suggested that diﬀerences in pyruvate metabolism might
lead to the disparity in taxadiene biosynthesis between a high-producing E. coli
strain and a low-producing one. [89]. An overexpression algorithm was employed
to identify the overexpression that could increase the taxadiene production ﬂux,
based on a transgenic E. coli genome-scale metabolic model with taxadiene
biosynthetic reactions included [90]. The following experiments conﬁrmed the
predicted results to a certain degree. Overexpression of the three predicted genes,
ppk (polyphosphate kinase), sthA (pyridine nucleotide transhydrogenase), and
purN (phosphoribosylglycinamide formyltransferase), with one key gene in MEP
pathway, idi (isopentenyl diphosphate isomerase), improved taxadiene titer over
12-fold as compared to the parent strain.
Since the expression of some of the genes originating from plants requires spe-
cialized environments or compartments, the host strain E. coli alone is not compe-
tent to produce subsequent metabolites after taxadiene in the paclitaxel pathway.
The production of taxadine-5𝛼-ol and taxadien-5𝛼-acetate-10𝛽-ol in E. coli and S.
cerevisiae consortium brings some inspirations in the heterologous production of
natural products: (i) we can take full usage of the properties in diﬀerent species;
And (ii) spatial segregation the whole pathway into diﬀerent microbes helps to
prevent some internal regulation in the pathway, and pathway modules can be
separately optimized.
“Omics” technologies have also been widely applied in Taxus sp. cell cultures,
tissues, and plants to ﬁnd the potential genes involved in paclitaxel synthesis.
Polymerase-chain reaction (PCR)-based suppression subtractive hybridization
(SSH) on a T. cuspidata cell line identiﬁed the genes upregulated or down-
regulated by MeJA [91]. Since the T. cuspidata cell line could produce higher
amounts of taxanes after MeJA elicitation, the upregulated cDNA library would
presumably include genes related to paclitaxel biosynthesis. Several genes pre-
viously known to be involved in the paclitaxel pathway were conﬁrmed to exist
in the upregulated library. Four putative taxadiene synthases, ﬁve novel putative
taxoid hydroxylases, and two newly identiﬁed candidate acyl transferases were
proposed in the analysis, which further enhanced the understanding of paclitaxel
biosynthesis. Hao et al. [92] de novo assembled the Taxus mairei transcriptome
using Illumina paired-end sequencing (RNA-seq) and investigated the transcrip-
tome diﬀerences among three T. mairei tissues: root, leaf, and stem. From the
Illumina dataset, 211 candidate genes involved in the paclitaxel biosynthetic
pathway were proposed. Transcriptome diﬀerences among plant tissues, as well as
the subsequent metabolome proﬁling, suggested that the expression of the taxane
biosynthetic genes remained highest in roots, which also had a relatively simple
metabolome proﬁle with large quantities of various taxanes, including paclitaxel.
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8.3.3
Podophyllotoxin Lignans
PTOX (Figure 8.5), an aryl tetralin lactone, is extracted mainly from the roots and
the rhizomes ofPodophyllum species. PTOXoccupies a special place among lignin
natural products, considering that its glucopyranoside derivatives have antitumor
functions. However, PTOX is too toxic to be applied in humans. Several semisyn-
thetic derivatives of PTOX (Figure 8.5) with lower toxicity, such as etoposide,
etopophos, and teniposide, are widely applied as anticancer drugs to treat lung
cancer, a variety of leukemia, and genital tumors [93–95].
P. hexandrum (in India and Nepal) and P. peltatum (in America) are the two
main Podophyllum species that produce PTOX. The rhizome of P. hexandrum
yields the highest amount of PTOX (4.3% of total dry weight), while the rhizome
of P. peltatum contains 0.3–1.0% PTOX by mass.
Over 40 plant and fungus species have been shown to produce PTOX. Callus,
cell, hairy root, and mycelial in vitro cultures of these species have been gener-
ated and tested for their potential for PTOX production.The few in vitro cultures
producing signiﬁcant amounts of PTOX are derived from Podophyllum sp., Cal-
litris drummondii, and the Iranian Linum species, mainly including L. album and
L. persicum [96]. Although the in vitro cultures of Podophyllum sp. can produce
considerable amounts of PTOX (up to 0.3% of DW), they grow very slowly and
are stressed, signiﬁed by the level of browning observed. Therefore, the in vitro
cultures of L. album have become more attractive because of their relatively fast
growth rate and abundance of PTOX.
The approaches that are commonly used to improve the in vitro production of
PTOX in plant organ cultures include optimization of cultivation, precursor feed-
ing, and elicitation [96]. The highest amount of PTOX (2.26% DW) was achieved
in the coculture of L. album suspension cells with the live fungus Sebacina ver-
mifera [97]. In addition, several endophytic fungi cultures have the capacity to
produce PTOX, such as Fusarium solani from P. hexandrum [98], Phialocephala
fortinii from P. peltatum [99], Trametes hirsuta from P. hexandrum [100], and
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Figure 8.5 Chemical structures of podophyllotoxin, etoposide, etopophos, and teniposide.
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F. oxysporum from Juniperus recurva [101]. The accumulation of PTOX in these
fungi is approximately 30 μg g−1 DW.
Presently, no metabolic engineering eﬀort of PTOX biosynthesis has been
reported. Rajesh et al. [24] developed an eﬃcient transformation protocol into
P. hexandrum embryogenic cells, providing a basis for future gene transfer into
PTOX-producing plants to optimize the production systems.
After the genes encoding the P450 enzyme pluviatolide synthase were dis-
covered in both P. hexandrum and P. peltatum via transcriptome analysis in
2013 [102], four subsequent genes in the PTOX biosynthetic pathway in P.
hexandrum were identiﬁed by Lau and Sattely in 2015 [103]. So far, only the
last enzyme catalyzing the conversion of deoxypodophyllotoxin to PTOX in
the PTOX biosynthesis is missing. In addition, Lau and Sattely also found two
more genes in the natural host, catalyzing the step from deoxypodophyllotoxin
to 4′-desmethyl-epipodophyllotoxin, which is a precursor to the semisynthetic,
clinically used reagent etoposide. The gene identiﬁcation process relied heavily
on analyzing the RNA-seq data or the transcriptome data. During the discovery
of pluviatolide synthase, sequence homology search was applied using double
criteria as query sequences; the ﬁrst one was to use nine diﬀerent known P450s
in plant secondary metabolism, and the second one was to use the enzymes with
the same catalytic function (the methylenedioxy bridge formation) in lignin and
alkaloid biosynthesis. In Lau and Sattely’s work, they compared the RNA-seq data
from wounded and unwounded leaf tissues to pinpoint the upregulated genes
since the PTOX pathway is more active in the wounded condition and further
narrowed down the range of gene candidates with the four predicted enzyme
types for the reactions in the PTOX pathway. With heterologous expression of
the gene candidates in Nicotiana benthamiana and the untargeted metabolite
proﬁling using mass spectrometry, six enzymes either in the original PTOX
pathway or in the other metabolite branches were identiﬁed (Figure 8.6).
8.3.4
Camptothecin Quinoline Alkaloids
CPT (Figure 8.7) is a modiﬁed MIA with the indole moiety changed to a
quinolone moiety during the CPT biosynthesis. CPT was ﬁrst isolated in 1958
from the extracts of the tree C. acuminate. In preclinical studies, CPT was found
eﬀective in curing colonic and gastric tumors [104]. The water-soluble CPT
semisynthetic derivatives irinotecan and topotecan (Figure 8.7) were approved
by FDA in 1996 to mainly treat ovarian, colon, and lung cancers. CPT has been
isolated from at least 16 diﬀerent angiosperms, and the current commercial
production of CPT is through extraction from the bark and seeds of C. acuminate
and Nothapodytes foetida. All plant organs of C. acuminate contain certain
amounts of CPT, among which young leaves have the highest level (∼0.4% DW,
50% and 250% higher than that in seeds and bark, respectively). Thus, repeated
harvest of C. acuminate young leaves without destroying the trees is a potentially
sustainable approach for CPT production [105].
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Figure 8.7 Chemical structures of camptothecin, irinotecan, and topotecan.
Numerous studies on the CPT production from C. acuminate, Ophiorrhiza
pumila, or N. foetida callus cell suspension, and hairy root cultures have been
reported. Generally, CPT levels in in vitro plant tissue cultures are 100- to
1000-fold lower than that in planta [106, 107]. To date, the highest reported yield
of CPT (1.3% DW) is from optimized callus cultures that were derived from
cotyledons of N. foetida [108]. The highest titers of secreted CPT (0.035mgml−1)
and the analog 9-methoxycamptothecin (0.026mgml−1) were observed in N.
foetida cell suspension culture medium [109]. Hairy root cultures induced
from three Ophiorrhiza species produced CPT, in which O. pumila hairy roots
accumulated the highest speciﬁc yield of CPT (0.08% DW) [110]. As in cell
suspension culture, the partially secreted CPT in hairy root culture facilitated
product enrichment by adding an absorbent resin [111]. Later, O. pumila hairy
root culture in a 3-l bioreactor was established with approximately 7mg l−1 total
CPT titer including 17% secreted CPT [112].
Entrophospora infrequens, one of the endophytic fungi isolated from the
twigs of N. foetida, was found to produce a relatively high speciﬁc yield of CPT,
4.96± 0.73mg 100 g−1 DW, in a bioreactor at 48 h [113]. Two endophytic fungi
strains of F. solani, isolated from Apodytes dimidiata, produced CPT (maximum
53 μg 100 g−1 DW) and its analogs 10-hydroxycamptothecin (maximum 8.2 μg
100 g−1 DW) and 9-methoxycamptothecin (maximum 44.9 μg 100 g−1 DW) after
4 days of incubation in broth culture [114]. Other fungi isolated either from C.
acuminate [115] or from N. foetida [116] also produced CPT and its analogs but
in small amounts (Figure 8.8).
Since vinca alkaloid-producing plants and CPT-producing plants share almost
the same strictosidine synthetic pathway, it would be possible to enhance CPT
production by introducing C. roseus genes encoding enzymes in the upstream of
the strictosidine pathway or encoding transcriptional activators of the whole TIA
pathway into CPT-producing plants. Geraniol-10-hydroxylase (G10H) has been
reported as a highly regulated enzyme in the upstream TIA pathway in C. roseus.
Co-overexpression ofG10HandSTR inO. pumilahairy root line led to an increase
of 56% on the CPT yield (1.77mg g−1 DW) compared with the non-engineered
hairy root line [117]. ORCA3 is a transcription factor fromC. roseus that activates
several genes in the whole TIA biosynthetic pathway. Ni et al. overexpressed the
ORCA3 gene inC. acuminate hairy root to study the eﬀect ofORCA3 regulator on
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CPT biosynthesis [118].The speciﬁc yield of CPT inORCA3 transgenic hairy root
lines increased 1.5-fold compared with the control, indicating that the ORCA3
regulator positively aﬀected CPT synthesis.
Several “omics” works have been conducted to further characterize the CPT
biosynthetic pathway. The transcriptomic datasets for three medicinal plants,
Camptotheca acuminata (producer of CPT), C. roseus, and Rauvolﬁa serpentina,
that produce various MIAs were obtained via next-generation sequencing
technology [119]. Mining of these datasets will enable the discovery of new
genes involved in MIAs pathway in the three species or even other species.
The combined analysis of transcriptomic datasets with untargeted metabolic
proﬁling datasets in O. pumila has further enhanced the understanding of the
CPT biosynthesis [120]. The untargeted metabolic proﬁling by Fourier transform
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ion cyclotron resonance-mass spectrometry (FTICR-MS) provided evidence for
identifying the possible intermediates during the reactions from strictosamide
to CPT. Metabolic proﬁling showed that CPT accumulated in hairy root culture
but not in suspension cells. Thus, the classiﬁcation of the P450s enzymes and
glycosidase-like proteins in the upregulated unigenes in hairy roots compared
with that in the cell suspension culture provided candidates of the P450s enzymes
and the glycosidase-like enzymes in the post-strictosamide CPT biosynthetic
pathway. Among all the candidate genes, the deglycosylation gene candidate was
proposed according to the sequence similarly to the reported analogous gene
from R. serpentina [121].
8.4
Prospects
8.4.1
Identiﬁcation of Intermediates in the Biosynthetic Pathways of Anticancer Drugs
Metabolomics or metabolite proﬁling is widely applied in drug discovery
and identiﬁcation of intermediates. Anticancer drugs are usually produced
through secondary metabolic pathways in plants, most of which have not
been well characterized because of the low levels of secondary metabolite
concentrations. In particular, the major part of the CPT biosynthetic path-
way is still undeﬁned. Typically, when referring to analytical instruments,
MS coupled with HPLC or gas chromatography (GC) is eﬀective for most
of the plant metabolic proﬁling and metabolomics, especially when high-
resolution MS and tandem MS techniques are put into practice. However,
the MS technique, even the tandem MS technique, cannot provide suﬃcient
information to identify the chemical structures of isomers. For instance, the
accurate molecular weights acquired by FTICR-MS helped to determine the
elemental composition of unknown metabolites in the proposed CPT biosyn-
thetic pathway, but no further structure analysis could be provided by MS
[120]. NMR is complementary to the MS-based metabolomics platform. In
recent years, HPLC-NMR has assisted in natural product proﬁling, especially
of marine natural products [122–124], which paves the way for metabolite
identiﬁcation and proﬁling in other plants. Secondly, metabolic diﬀerential
accumulation in diverse plant tissues, in diﬀerent in vitro cultures or in var-
ious environments, facilitates the search for target metabolites. Finally, new
plant reference biochemical databases and metabolite proﬁle databases are
needed in the future. Until recently, metabolite proﬁle databases were scarce,
whereas several microarray databases, including ArrayExpress and Gene
Expression Omnibus (GEO), have stored gene expression data [125]. Archiving
metabolite proﬁle data in a speciﬁed format would undoubtedly facilitate data
sharing.
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8.4.2
Discovery of Unknown Genes in Biosynthetic Pathways
Among the four categories of anticancer drugs, most of the genes in the biosyn-
thetic pathways of vinca alkaloids, taxane diterpenoids, and PTOX lignans have
been identiﬁed from extensive research studies using diverse gene character-
ization techniques. However, there are still several uncharacterized reactions
in the pathways that block the strategy of importing the entire pathways into
heterologous hosts. In order to further discover unknown genes, deeper “omics”
techniques, especially proteomics and transcriptomics diﬀerential expression in
diverse explant types, diﬀerent growth stages, or various induction conditions,
are needed to facilitate the determination of putative gene candidates. Alex
et al. not only built the CathaCyc database but also integrated the transcriptome
expression levels of the known genes in secondary metabolism in 23 diﬀerent
tissues and treatments to establish a hierarchical cluster of these genes [61]. This
research can be extended to collect all the RNA-seq data of diﬀerent tissues and
treatments in C. roseus and build a more accurate hierarchical cluster based
on the transcriptome diﬀerential expression. This approach would provide a
more reliable and accurate means to further pinpoint the target genes. A similar
strategy can also be applied to proteomics. Even without the aforementioned
“omics” analysis, screening a cDNA library to characterize genes in either plant
hosts or microbial hosts is a feasible technique, especially for the genes involved
in the plant stress response pathways [126, 127].
8.4.3
Production of Anticancer Drugs in Microbial Hosts
Besides producing anticancer drugs in homologous and heterologous plant
tissue cultures, production of plant-derived secondary metabolites in microbial
hosts is a promising avenue despite several challenges. Taxane diterpenoids
could become the ﬁrst case among all the plant-derived anticancer drugs that
are produced in microbial hosts because of their relatively well-characterized
pathways. The biggest issue is how to eﬃciently express plant cytochrome
P450 enzymes in microbes, such as E. coli and S. cerevisiae. Ajikumar et al.
have applied the transmembrane engineering strategy and generated chimera
enzymes composed of P450 and CYP450-reductase (CPR) to convert taxadiene
to taxadien-5𝛼-ol [15]. Cytochrome b5 reportedly enhances the activity of certain
cytochrome P450s [128]. Therefore, coexpression of P450s together with CPR
and cytochrome b5 may increase the enzyme activity. On the other hand, how
to maximize and balance the ﬂux toward the target product and minimize the
ﬂux into byproducts is the key to heterologous production. Here, the substantial
body of work in microbial metabolic pathway engineering, including integration
of computation analysis with ﬂux measurements and a genome-scale model, can
shorten the development time for strain design [129].
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